ResMed Inc. (NYSE:RMD) Receives Average Recommendation of “Hold” from Brokerages

Posted by Brenda Bartman on Sep 6th, 2026

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) have been given a consensus rating of “Hold” by the sixteen research firms that are presently covering the firm, MarketBeat Ratings reports. Ten research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $240.3077.

A number of equities research analysts have commented on RMD shares. Mizuho decreased their target price on shares of ResMed from $235.00 to $220.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Weiss Ratings upgraded shares of ResMed from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Royal Bank Of Canada raised their price objective on shares of ResMed from $234.00 to $244.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Jefferies Financial Group decreased their price target on ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a report on Friday, July 10th. Finally, Wells Fargo & Company lowered their price objective on ResMed from $225.00 to $215.00 and set an “equal weight” rating on the stock in a research report on Friday, August 7th.

Read Our Latest Stock Report on RMD

ResMed Stock Performance

NYSE:RMD opened at $228.25 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.42 and a current ratio of 3.10. The stock has a 50-day simple moving average of $215.51 and a two-hundred day simple moving average of $218.22. The firm has a market capitalization of $32.93 billion, a PE ratio of 21.88, a P/E/G ratio of 1.43 and a beta of 0.77. ResMed has a 52-week low of $180.26 and a 52-week high of $284.87.

ResMed (NYSE:RMD – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 EPS for the quarter, topping the consensus estimate of $2.89 by $0.06. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.46 billion. ResMed had a return on equity of 25.58% and a net margin of 26.94%.The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.55 earnings per share. Analysts forecast that ResMed will post 12.02 EPS for the current year.

ResMed Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 24th. Investors of record on Thursday, August 20th will be issued a $0.66 dividend. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $2.64 dividend on an annualized basis and a yield of 1.2%. This is a boost from ResMed’s previous quarterly dividend of $0.60. ResMed’s payout ratio is presently 25.31%.

Insider Activity at ResMed

In other news, Director Peter Farrell sold 8,000 shares of ResMed stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,800,000.00. Following the sale, the director owned 52,773 shares in the company, valued at $11,873,925. This trade represents a 13.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Farrell sold 4,991 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the completion of the transaction, the chief executive officer directly owned 466,223 shares in the company, valued at $101,893,036.65. This trade represents a 1.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 23,943 shares of company stock valued at $5,113,124 over the last 90 days. 0.65% of the stock is currently owned by corporate insiders.

Institutional Trading of ResMed

A number of large investors have recently added to or reduced their stakes in the company. Terra Nova Asset Management LLC grew its holdings in shares of ResMed by 0.6% in the third quarter. Terra Nova Asset Management LLC now owns 7,805 shares of the medical equipment provider’s stock valued at $2,136,000 after purchasing an additional 46 shares in the last quarter. Kera Capital Partners Inc. boosted its holdings in shares of ResMed by 6.6% in the 4th quarter. Kera Capital Partners Inc. now owns 841 shares of the medical equipment provider’s stock worth $217,000 after purchasing an additional 52 shares during the period. Andina Capital Management LLC increased its position in shares of ResMed by 2.9% during the 4th quarter. Andina Capital Management LLC now owns 1,988 shares of the medical equipment provider’s stock valued at $479,000 after purchasing an additional 56 shares during the last quarter. Turtle Creek Wealth Advisors LLC increased its position in shares of ResMed by 6.2% during the 1st quarter. Turtle Creek Wealth Advisors LLC now owns 994 shares of the medical equipment provider’s stock valued at $223,000 after purchasing an additional 58 shares during the last quarter. Finally, Inspire Investing LLC raised its holdings in ResMed by 7.9% during the 4th quarter. Inspire Investing LLC now owns 902 shares of the medical equipment provider’s stock valued at $217,000 after buying an additional 66 shares during the period. Institutional investors own 54.98% of the company’s stock.

About ResMed

(Get Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.